Abstract
A synthesis of a novel and chemically stable homoisocarbacyclin analog, TY-11223 (3___-), has been accomplished.The analog (3___-), given intravenously or orally, showed potent and long-lasting activities in inhibiting platelet aggregation and, in addition, a good selectivity in biological activities.